Human Leukocyte Antigen Matching Estimations in a Hypothetical Bank of Human Embryonic Stem Cell Lines in the Japanese Population for Use in Cell Transplantation Therapy
The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Human embryonic stem (hES) cell lines are of great potential in cell transplantation therapy. However, recipients of such allogeneic transplants probably need treatment with immunosuppressants. Recently, Taylor et al. [Lancet 2005;366:2019-2025] proposed banking of hES cell lines and estimated the required number of hES cell lines for beneficial human leukocyte antigen (HLA) matching in the U.K. population. Here, we carried out such an estimation in the Japanese population. We calculated the proportion of patients who can find at least one HLA-matched donor at three loci of HLA-A, -B, and -DR. With a bank of hES cell lines from 170 randomly selected donated embryos, 80% of patients were expected to find at least one hES cell line with a single mismatch at one HLA locus or a better match. Furthermore, 80% of patients are expected to find at least one donor with complete matching at the three HLA loci if parthenogenetic homozygous hES cell lines are established from 55 randomly selected donated oocytes. The relatively low ethnic diversity of the Japanese population may have resulted in a high success rate in beneficial matching. Moreover, parthenogenetic hES cell lines can greatly reduce the number required for a higher degree of HLA matching.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For instance, an HLA iPSC bank with iPSCs derived from 55 donors can be used to perform iPSC-based cell therapy for 80% of the Japanese population, a country with limited HLA variability [106].”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [106]
Citations
Cites
Takahashi, K., & Yamanaka, S. (2006) · Cell · doi:10.1016/j.cell.2006.07.024 · Cited by 26,673
Embryonic Stem Cell Lines Derived from Human Blastocysts
Thomson, J. A., Itskovitz-Eldor, J., Shapiro, S. S., Waknitz, M. A., Swiergiel, J. J., Marshall, V. S., & Jones, J. M. (1998) · Science · doi:10.1126/science.282.5391.1145 · Cited by 15,926
Embryonic stem cell lines from human blastocysts: somatic differentiation in vitro
Reubinoff, B. E., Pera, M. F., Fong, C.-Y., Trounson, A., & Bongso, A. (2000) · Nature Biotechnology · doi:10.1038/74447 · Cited by 2,706
Taylor, C. J., Bolton, E. M., Pocock, S., Sharples, L. D., Pedersen, R. A., & Bradley, J. A. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67813-0 · Cited by 493
Petersdorf, E. W., Gooley, T. A., Anasetti, C., Martin, P. J., Smith, A. G., Mickelson, E. M., Woolfrey, A. E., & Hansen, J. A. (1998) · Blood · doi:10.1182/blood.v92.10.3515 · Cited by 480
Drukker, M., Katchman, H., Katz, G., Even-Tov Friedman, S., Shezen, E., Hornstein, E., Mandelboim, O., Reisner, Y., & Benvenisty, N. (2006) · Stem Cells · doi:10.1634/stemcells.2005-0188 · Cited by 402
Parthenogenetic Stem Cells in Nonhuman Primates
Cibelli, J. B., Grant, K. A., Chapman, K. B., Cunniff, K., Worst, T., Green, H. L., Walker, S. J., Gutin, P. H., Vilner, L., Tabar, V., et al. (2002) · Science · doi:10.1126/science.1065637 · Cited by 311
Suemori, H., Yasuchika, K., Hasegawa, K., Fujioka, T., Tsuneyoshi, N., & Nakatsuji, N. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.04.135 · Cited by 300
HLA Typing and Its Influence on Organ Transplantation
Sheldon, S., & Poulton, K. (2006) · Humana Press eBooks · doi:10.1385/1-59745-049-9:157 · Cited by 130
Navarro, V. J., Herrine, S. K., Katopes, C., Colombe, B., & Spain, V. C. (2006) · Liver Transplantation · doi:10.1002/lt.20680 · Cited by 96
Research works printed but not linked: 1
- Imanishi, 1992, HLA 1991, 76
Cited by
iPS cells: a game changer for future medicine
Inoue, H., Nagata, N., Kurokawa, H., & Yamanaka, S. (2014) · The EMBO Journal · doi:10.1002/embj.201387098 · Cited by 405
“One of the most feasible methods for iPSC therapy, therefore, will be based on the collection of iPSC stocks derived from various HLA-homozygous donors under Good Manufacturing Practice (GMP) compliance (Nakajima et al, 2007; Okita et al, 2011; Takahashi & Yamanaka, 2013).”
MethodHLA-haplotype banking and iPS cells
Nakatsuji, N., Nakajima, F., & Tokunaga, K. (2008) · Nature Biotechnology · doi:10.1038/nbt0708-739 · Cited by 336
Prospects for Stem Cell-Based Therapy
Daley, G. Q., & Scadden, D. T. (2008) · Cell · doi:10.1016/j.cell.2008.02.009 · Cited by 302
“A simulation performed within a Japanese cohort concluded that 100 homozygous donors could match 80% of the recipients (Nakajima et al., 2007).”
MethodGenomic Instability of iPSCs: Challenges Towards Their Clinical Applications
Yoshihara, M., Hayashizaki, Y., & Murakawa, Y. (2017) · Stem Cell Reviews and Reports · doi:10.1007/s12015-016-9680-6 · Cited by 283
“Importantly, a small number of homozygous human leukocyte antigen (HLA) types could cover a large portion of populations [80, 81], making them ideal biological resources for allogeneic transplantation [79].”
BackgroundInduced pluripotent stem cells in medicine and biology
Takahashi, K., & Yamanaka, S. (2013) · Development · doi:10.1242/dev.092551 · Cited by 265
“Thus, at present, the most realistic method for iPSC therapy is based on the collection of iPSC stocks derived from various HLA-homozygous donors (Nakajima et al., 2007; Okita et al., 2011).”
MethodThe Promise and Perils of Stem Cell Therapeutics
Daley, G. Q. (2012) · Cell Stem Cell · doi:10.1016/j.stem.2012.05.010 · Cited by 259
Cell therapy for the treatment of coronary heart disease: a critical appraisal
Wollert, K. C., & Drexler, H. (2010) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2010.1 · Cited by 251
“An alternative approach would be to compile cell banks of pluripotent stem cell lines ready for off-the-shelf use”
BackgroundTeratomas from pluripotent stem cells: A clinical hurdle
Fong, C., Gauthaman, K., & Bongso, A. (2010) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22775 · Cited by 222
Dental Pulp Cells for Induced Pluripotent Stem Cell Banking
Tamaoki, N., Takahashi, K., Tanaka, T., Ichisaka, T., Aoki, H., Takeda-Kawaguchi, T., Iida, K., Kunisada, T., Shibata, T., Yamanaka, S., et al. (2010) · Journal of Dental Research · doi:10.1177/0022034510366846 · Cited by 221
“estimated that a collection of 50 unique iPS cell lines having homozygous alleles of the 3 HLA loci (A, B, and DR) would cover ~ 90% of the Japanese population with a perfect match of these loci (Nakajima et al., 2007; Nakatsuji et al., 2008).”
BackgroundStem cell based therapies for age-related macular degeneration: The promises and the challenges
Nazari, H., Zhang, L., Zhu, D., Chader, G. J., Falabella, P., Stefanini, F., Rowland, T., Clegg, D. O., Kashani, A. H., Hinton, D. R., et al. (2015) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2015.06.004 · Cited by 206
“…it is necessary to have a rough estimate of how many different RPE cell lines would need to be in such a pool to have themaximumnumber of possible combinations of factors to match to donors as has been reported by Taylor et al. and Nakajima et al. (Taylor et al., 2005; Nakajima et al., 2007).”
BackgroundCritical issues of clinical human embryonic stem cell therapy for brain repair
Li, J.-Y., Christophersen, N. S., Hall, V., Soulet, D., & Brundin, P. (2008) · Trends in Neurosciences · doi:10.1016/j.tins.2007.12.001 · Cited by 192
“The creation of such a bank of human leukocyte antigen (HLA)-typed hESCs might be feasible [61, 62 ].”
Gasparini, S. J., Llonch, S., Borsch, O., & Ader, M. (2019) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2018.11.001 · Cited by 186
Concise Review: Human Embryonic Stem Cells—What Have We Done? What Are We Doing? Where Are We Going?
Ilic, D., & Ogilvie, C. (2017) · Stem Cells · doi:10.1002/stem.2450 · Cited by 179
Present and future challenges of induced pluripotent stem cells
Ohnuki, M., & Takahashi, K. (2015) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2014.0367 · Cited by 174
Hurdles to clinical translation of human induced pluripotent stem cells
Neofytou, E., O’Brien, C. G., Couture, L. A., & Wu, J. C. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80575 · Cited by 166
Gourraud, P.-A., Gilson, L., Girard, M., & Peschanski, M. (2012) · Stem Cells · doi:10.1002/stem.772 · Cited by 163
Hartman, M. E., Dai, D.-F., & Laflamme, M. A. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.05.004 · Cited by 138
“This strategy would likely also require the banking of diverse human leukocyte antigen (HLA) typed PSCs, and many dozens of human PSC lines would be needed to ensure a reasonable chance of a suitable match even in patient populations with relatively low ethnic diversity [179, 180].”
BackgroundLin, G., OuYang, Q., Zhou, X., Gu, Y., Ding, Y., Li, W., Liu, G., Liu, T., & Lu, G. (2007) · Cell Research · doi:10.1038/cr.2007.97 · Cited by 130
Targeting innate immunity for neurodegenerative disorders of the central nervous system
Andreasson, K. I., Bachstetter, A. D., Colonna, M., Ginhoux, F., Holmes, C., Lamb, B., Landreth, G., Lee, D. C., Low, D., Lynch, M. A., et al. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13667 · Cited by 126
Hulot, J.-S., Stillitano, F., Salem, J. E., Kovacic, J. C., Fuster, V., & Hajjar, R. J. (2014) · Stem Cell Research & Therapy · doi:10.1186/scrt390 · Cited by 126
“reported that the generation of 50 iPSC lines would be sufficient to cover 90% of the Japanese population [46].”
BackgroundStem cell therapy for cardiac disease
Bernstein, H. S., & Srivastava, D. (2012) · Pediatric Research · doi:10.1038/pr.2011.61 · Cited by 130
“Although the prospect of iPSC banking to provide “off-the-shelf ” therapy may be useful in genetically homogeneous populations (71,72), this approach may not be practical in more diverse communities (73).”
Parthenogenetic stem cells for tissue-engineered heart repair
Didié, M., Christalla, P., Rubart, M., Muppala, V., Döker, S., Unsöld, B. W., El‐Armouche, A., Rau, T., Eschenhagen, T., Schwoerer, A. P., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66854 · Cited by 119
“MHC haploidentity is considered immunologically advantageous in allotransplantation (20, 21).”
InfluentialLee, S., Huh, J. Y., Turner, D. M., Lee, S., Robinson, J., Stein, J. E., Shim, S. H., Hong, C. P., Kang, M. S., Nakagawa, M., et al. (2018) · Stem Cells · doi:10.1002/stem.2865 · Cited by 99
HLA-Matching Potential of an Established Human Embryonic Stem Cell Bank in China
Lin, G., Xie, Y., OuYang, Q., Qian, X., Xie, P., Zhou, X., Xiong, B., Tan, Y., Li, W., Deng, L., et al. (2009) · Cell stem cell · doi:10.1016/j.stem.2009.10.009 · Cited by 97
Potential and Limitation of HLA-Based Banking of Human Pluripotent Stem Cells for Cell Therapy
de Rham, C., & Villard, J. (2014) · Journal of Immunology Research · doi:10.1155/2014/518135 · Cited by 96
“[23] both answered this question for their own countries, United Kingdom and Japan, respectively.”
BackgroundThe safety of human pluripotent stem cells in clinical treatment
Simonson, O. E., Domogatskaya, A., Volchkov, P., & Rodin, S. (2015) · Annals of Medicine · doi:10.3109/07853890.2015.1051579 · Cited by 97
Banking on iPSC- Is it Doable and is it Worthwhile
Solomon, S., Pitossi, F., & Rao, M. S. (2015) · Stem Cell Reviews and Reports · doi:10.1007/s12015-014-9574-4 · Cited by 86
“Similar data with mismatched or allogeneic MSC suggest that MSC while not immune privileged are immunomodulatory and do not provoke a large rejection response and in many instances can tamp down a immune response [63–65].”
ResultMending a broken heart: current strategies and limitations of cell-based therapy
Liew, L. C., Ho, B. X., & Soh, B.-S. (2020) · Stem Cell Research & Therapy · doi:10.1186/s13287-020-01648-0 · Cited by 97
“Alternatively, the establishment of diverse human leukocyte antigen (HLA) typed PSC line has also been suggested to expand the number of target patients that can benefit from PSC-based cardiac therapy [162, 163].”
BackgroundStephenson, E., Jacquet, L., Miere, C., Wood, V. H. J., Kadeva, N., Cornwell, G., Codognotto, S., Dajani, Y., Braude, P., & Ilić, D. (2012) · Nature Protocols · doi:10.1038/nprot.2012.080 · Cited by 75
Higuchi, A., Ling, Q., Kumar, S. S., Chang, Y., Alarfaj, A. A., Munusamy, M. A., Murugan, K., Hsu, S.-T., & Umezawa, A. (2015) · Journal of Materials Chemistry B · doi:10.1039/c5tb01276g · Cited by 83
Induced pluripotent stem (iPS) cells: A new source for cell-based therapeutics?
de Lázaro, I., Yılmazer, A., & Kostarelos, K. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.04.011 · Cited by 82
“Although at first glance this would act as a detriment of the notion of personalized iPS cell therapy, it has been calculated that a stock of 75 iPS cell lines derived fromhomozygous human leukocyte antigen (HLA) donors would be enough to match 80% of the population in Japan without triggering any immune response [34,…”
Fraga, A. M., Sukoyan, M. A., Rajan, P., Braga, D. P. D. A. F., Iaconelli, A., Franco, J. G., Jr., Borges, E., & Pereira, L. V. (2010) · Cell Transplantation · doi:10.3727/096368910x522261 · Cited by 70
The Challenge of Bringing iPSCs to the Patient
Ortuño‐Costela, M. D. C., Cerrada, V., García‐López, M., & Gallardo, M. E. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20246305 · Cited by 76
“The proposal would be to create an iPSCs bank from HLA-homozygous and blood group O donors, simplifying the patient-donor matching [87].”
BackgroundAllogenic banking of dental pulp stem cells for innovative therapeutics.
Collart-Dutilleul, P.-Y., Chaubron, F., Vos, J. D., & Cuisinier, F. (2015) · World Journal of Stem Cells · doi:10.4252/wjsc.v7.i7.1010 · Cited by 88
Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy
Nicholson, M. W., Ting, C.-Y., Chan, D. Z. H., Cheng, Y.-C., Lee, Y.-C., Hsu, C.-C., Huang, C.-Y., & Hsieh, P. C. H. (2022) · Cells · doi:10.3390/cells11111853 · Cited by 65
Pluripotent Stem Cells for Retinal Tissue Engineering: Current Status and Future Prospects
Singh, R. K., Cuzzani, O., Binette, F., Sternberg, H., West, M. D., & Nasonkin, I. O. (2018) · Stem Cell Reviews and Reports · doi:10.1007/s12015-018-9802-4 · Cited by 69
Zimmermann, A., Preynat-Seauve, O., Tiercy, J.-M., Krause, K.-H., & Villard, J. (2012) · Stem Cells and Development · doi:10.1089/scd.2012.0088 · Cited by 62
“This was reiterated in the study by Nakajima et al. [50] where it was suggested that 55 randomly selected homozygous embryos could produce lines to provide a perfect match for 80% of the population.”
A Feeder-Free and Efficient Production of Functional Neutrophils from Human Embryonic Stem Cells
Saeki, K., Saeki, K., Nakahara, M., Matsuyama, S., Nakamura, N., Yogiashi, Y., Yoneda, A., Koyanagi, M., Kondo, Y., & Yuo, A. (2008) · Stem Cells · doi:10.1634/stemcells.2007-0980 · Cited by 63
Azuma, K., & Yamanaka, S. (2016) · Regenerative Therapy · doi:10.1016/j.reth.2016.01.009 · Cited by 63
Embryonic Stem Cells in Clinical Trials: Current Overview of Developments and Challenges
Golchin, A., Chatziparasidou, A., Ranjbarvan, P., Niknam, Z., & Ardeshirylajimi, A. (2020) · Advances in experimental medicine and biology · doi:10.1007/5584_2020_592 · Cited by 70
Regulatory Issues for Personalized Pluripotent Cells
Condic, M. L., & Rao, M. S. (2008) · Stem Cells · doi:10.1634/stemcells.2008-0421 · Cited by 61
Genomic Instability of iPSCs and Challenges in Their Clinical Applications
Yoshihara, M., Oguchi, A., & Murakawa, Y. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-31206-0_2 · Cited by 60
Setting Up a Haplobank: Issues and Solutions
Barry, J., Hyllner, J., Stacey, G., Taylor, C. J., & Turner, M. (2015) · Current Stem Cell Reports · doi:10.1007/s40778-015-0011-7 · Cited by 59
Decreased Risk of Graft Failure with Maternal Liver Transplantation in Patients with Biliary Atresia
Nijagal, A., Fleck, S., Hills, N. K., Feng, S., Tang, Q., Kang, S., Rosenthal, P. J., & MacKenzie, T. C. (2011) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2011.03895.x · Cited by 56
“We reviewed all pediatric (age 0–6 years) primary isolated split liver transplants performed in the United States from 1996 to 2010 as recorded in the SRTR database.”
ResultStrategy for the creation of clinical grade hESC line banks that HLA‐match a target population
Jacquet, L., Stephenson, E., Collins, R., Patel, H., Trussler, J., Al‐bedaery, R., Renwick, P., Ogilvie, C. M., Vaughan, R., & Ilić, D. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201201973 · Cited by 56
“No financial inducements are offered for donation.”
Daughtry, B. L., & Mitalipov, S. M. (2014) · Stem Cells Translational Medicine · doi:10.5966/sctm.2013-0127 · Cited by 58
Vascular differentiation from embryonic stem cells: Novel technologies and therapeutic promises
Descamps, B., & Emanueli, C. (2012) · Vascular Pharmacology · doi:10.1016/j.vph.2012.03.007 · Cited by 58
Ambasudhan, R., Dolatabadi, N., Nutter, A., Masliah, E., McKercher, S. R., & Lipton, S. A. (2014) · The Journal of Comparative Neurology · doi:10.1002/cne.23617 · Cited by 45
“MEF2 is antiapoptotic (Mao et al. 1999; Okamoto et al., 2000; Li Z et al., 2008), a property that will promote graft survival.”
BackgroundLee, J. E., Kang, M. S., Park, M. H., Shim, S. H., Yoon, T. K., Chung, H., & Lee, D. R. (2010) · Cell Transplantation · doi:10.3727/096368910x513991 · Cited by 47
The promise of human embryonic stem cells in aging-associated diseases
Yabut, O., & Bernstein, H. S. (2011) · Aging · doi:10.18632/aging.100328 · Cited by 59
“[94] estimated that approximately 170 hESC lines, or 55 hESC lines with homozygous HLA types, would be sufficient for 80% of patients in the Japanese population.”
BackgroundModeling rare diseases with induced pluripotent stem cell technology
Anderson, R. H., & Francis, K. R. (2018) · Molecular and Cellular Probes · doi:10.1016/j.mcp.2018.01.001 · Cited by 53
Generation of universal and hypoimmunogenic human pluripotent stem cells
Ye, Q., Sung, T., Yang, J., Ling, Q., He, Y., & Higuchi, A. (2020) · Cell Proliferation · doi:10.1111/cpr.12946 · Cited by 48
Potential use of endothelial progenitor cells for regeneration of the vasculature
Yamahara, K., & Itoh, H. (2009) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944708097728 · Cited by 50
“Recently, Taylor et al. [2005] proposed the creation of a bank of HLA-typed human ES cells from which a best match could be selected, helping to reduce the likelihood of graft rejection [Nakajima et al. 2007; Taylor et al. 2005].”
BackgroundFurth, M. E., & Atala, A. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-398358-9.00006-9 · Cited by 55
Moon, S., Kim, J. S., Park, S., Lee, H. J., Tae, J., & Chung, H. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.05.026 · Cited by 38
Population-based high-throughput toxicity screen of human iPSC-derived cardiomyocytes and neurons
Huang, C. Y., Nicholson, M. W., Wang, J. Y., Ting, C. Y., Tsai, M. H., Cheng, Y. C., Liu, C. L., Chan, D. Z. H., Lee, Y. C., Hsu, C. C., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110643 · Cited by 36
Advancing a Stem Cell Therapy for Age-Related Macular Degeneration
O'Neill, H. C., Limnios, I. J., & Barnett, N. L. (2019) · Current Stem Cell Research & Therapy · doi:10.2174/1574888x15666191218094020 · Cited by 41
Hasegawa, K., Zhang, P., Wei, Z., Pomeroy, J. E., Lu, W., & Pera, M. F. (2010) · Stem Cells · doi:10.1002/stem.466 · Cited by 36
Petrash, C. C., Palestine, A. G., & Canto-Soler, M. V. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.621007 · Cited by 38
Embryonic and embryonic-like stem cells in heart muscle engineering
Zimmermann, W. (2010) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2010.10.027 · Cited by 36
Breckwoldt, K., Weinberger, F., & Eschenhagen, T. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2015.11.010 · Cited by 36
Selvakumar, D., Reyes, L., & Chong, J. J. H. (2022) · Current Cardiology Reports · doi:10.1007/s11886-022-01666-9 · Cited by 30
Personalizing Stem Cell Research and Therapy: The Arduous Road Ahead or Missed Opportunity?
Patel, S. A., King, C., Lim, P. K., Habiba, U., Dave, M. A., Porecha, R., & Rameshwar, P. (2010) · Current pharmacogenomics and personalized medicine (Online)/Current pharmacogenomics and personalized medicine · doi:10.2174/1875692111008010025 · Cited by 27
Advances in Reprogramming-Based Study of Neurologic Disorders
Nityanandam, A., & Baldwin, K. K. (2015) · Stem Cells and Development · doi:10.1089/scd.2015.0044 · Cited by 31
“Due to the economic and logistical hurdles associated with this approach, scientists have suggested creating HLA-matched iPSC banks that could provide nonimmunogenic cells for therapy to a large percentage of the human population [225,226].”
BackgroundCentralized Banks for Human Embryonic Stem Cells: A Worthwhile Challenge
O'Rourke, P. P., Abelman, M., & Heffernan, K. G. (2008) · Cell stem cell · doi:10.1016/j.stem.2008.03.018 · Cited by 25
“Prominent researchers (Taylor et al., 2005; Nakajima et al., 2007) have conjectured that banks could ultimately include and make available clinical-grade hLA-typed hESC cells.”
BackgroundiPS Cells—The Triumphs and Tribulations
Sharma, R. (2016) · Dentistry Journal · doi:10.3390/dj4020019 · Cited by 27
“would cover 90% of the Japanese population with a faultless match of these loci [105,106].”
BackgroundPromises and Challenges of Stem Cell Research for Regenerative Medicine
Power, C. A., & Rasko, J. E. J. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-155-10-201111150-00010 · Cited by 27
“Another strategy is to establish large ES cell banks from which histocompatible matches could be selected (43, 44).”
BackgroundCurrent Landscape of iPSC Haplobanks
Escribá, R., Beksaç, M., Griscelli, A. B., Glover, J. C., Koskela, S., Latsoudis, H., Querol, S., & Álvarez-Palomo, B. (2024) · Stem Cell Reviews and Reports · doi:10.1007/s12015-024-10783-7 · Cited by 30
“Similarly, a study with 2,578 unrelated Japanese individuals estimated that 55 HLA-homozygous hESC lines would cover 80% of the respective population [15].”
BackgroundDiverging Concepts and Novel Perspectives in Regenerative Medicine
Muraca, M., Piccoli, M., Franzin, C., Tolomeo, A. M., Jurga, M., Pozzobon, M., & Perilongo, G. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18051021 · Cited by 26
“The development of broadly human leukocyte antigen (HLA)-compatible cell lines was theorized a decade ago [40].”
BackgroundMaking it personal: The prospects for autologous pluripotent stem cell-derived therapies
Blair, N. F., & Barker, R. A. (2016) · Regenerative Medicine · doi:10.2217/rme-2016-0057 · Cited by 22
Kumar, A., Lee, J. H., Suknuntha, K., D'Souza, S. S., Thakur, A. S., & Slukvin, I. I. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1801027 · Cited by 22
“Mouse OP9 stromal cells were provided by Dr. T. Nakano (Osaka University, Osaka, Japan).”
BackgroundInfluentialA Survey of Parameters Involved in the Establishment of New Lines of Human Embryonic Stem Cells
Fraga, A. M., de Araújo, É. S. S., Stabellini, R., Vergani, N., & Pereira, L. V. (2011) · Stem Cell Reviews and Reports · doi:10.1007/s12015-011-9250-x · Cited by 21
“Moreover, if they are intended to be used as sources of tissues for transplants, there may be a need for HLA matching between the hESCs and patients, and thus the establishment of a large number of HLA-diverse hESC lines is required [7, 8].”
BackgroundTakahashi, K. (2010) · Development Growth & Differentiation · doi:10.1111/j.1440-169x.2010.01169.x · Cited by 21
“B, and –DR (Nakajima et al. 2007).”
BackgroundDeveloping Cell-Based Therapies for RPE-Associated Degenerative Eye Diseases
M’Barek, K. B., Habeler, W., Régent, F., & Monville, C. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-28471-8_3 · Cited by 19
Daley, G. Q. (2007) · Hematology · doi:10.1182/asheducation-2007.1.17 · Cited by 19
Stem Cell Therapy to Treat Diabetes Mellitus
Liew, C. G., & Andrews, P. W. (2008) · The Review of Diabetic Studies · doi:10.1900/rds.2008.5.203 · Cited by 19
“(2006) also estimated that with a bank of HESC lines from 170 randomly selected donated embryos, 80% of the patients could be expected to find at least one HESC line with only a single mismatch at one HLA locus or even a better match [118].”
BackgroundConcise Review: Epidermal Grafting: The Case for Pluripotent Stem Cells
Lemaître, G., Nissan, X., Baldeschi, C., & Peschanski, M. (2011) · Stem Cells · doi:10.1002/stem.636 · Cited by 21
Dental applications of induced pluripotent stem cells and their derivatives
Gao, P., Liu, S., Wang, X., & Ikeya, M. (2022) · Japanese Dental Science Review · doi:10.1016/j.jdsr.2022.03.002 · Cited by 18
“Fifty iPSC cell lines containing the same 3-HLA-loci could cover 90% of the Japanese population with perfect matches for these loci [121,122].”
BackgroundDonor Recruitment and Eligibility Criteria for HLA-Homozygous iPS Cell Bank in Japan
Saito, M. K., Matsunaga, A., Takasu, N., & Yamanaka, S. (2014) · Stem cell biology and regenerative medicine · doi:10.1007/978-1-4939-0585-0_7 · Cited by 17
“7 % of the population [ 4 , 5 ].”
Cardiac Repair and Restoration Using Human Embryonic Stem Cells
Bernstein, H. S. (2012) · Regenerative Medicine · doi:10.2217/rme.12.46 · Cited by 16
Kim, A., Lee, K., Kwon, Y., Lee, K.-I., Yang, H.-M., Habib, O., Kim, J., Kim, S. J., Kim, J., Kim, J., et al. (2020) · Stem Cell Reviews and Reports · doi:10.1007/s12015-020-10113-7 · Cited by 17
“One study estimated that 55 parthenogenetic HLA-homozygous hESC lines derived from randomly donated embryos could provide a full match of HLA-A, -B, and -DR for 80% of the Japanese population [13].”
BackgroundCooper, O., Parmar, M., & Isacson, O. (2012) · Progress in brain research · doi:10.1016/b978-0-444-59575-1.00012-0 · Cited by 17
Banking Human Pluripotent Stem Cell Lines for Clinical Application?
Nakatsuji, N. (2010) · Journal of Dental Research · doi:10.1177/0022034510375288 · Cited by 16
“Our group later published the supportive potential of banking conventional or parthenogenetic hESC lines (Nakajima et al., 2007), with projections for the Japanese population.”
Human pluripotent stem cells: From biology to cell therapy
Ramirez, J., Bai, Q., Dijon-Grinand, M., Assou, S., Gerbal‐Chaloin, S., Hamamah, S., & Vos, J. D. (2010) · World Journal of Stem Cells · doi:10.4252/wjsc.v2.i2.24 · Cited by 17
Derivation of a Homozygous Human Androgenetic Embryonic Stem Cell Line
Ding, C., Huang, S., Quan, Q., Fu, R., Zhu, W., Cai, B., Hong, P., Liu, Z., Gu, T., Zeng, Y., et al. (2015) · Stem Cells and Development · doi:10.1089/scd.2015.0031 · Cited by 15
“For example, 55 randomly selected homozygous pESC lines could completely match 80% of the Japanese patients at three important HLA loci (A, B, and DR) [21].”
Potential applications of keratinocytes derived from human embryonic stem cells
Movahednia, M. M., Kidwai, F. K., Jokhun, D. S., Squier, C. A., Toh, W. S., & Cao, T. (2015) · Biotechnology Journal · doi:10.1002/biot.201500099 · Cited by 15
“Moreover, it is proposed that hESCs banked with three major human leucocyte antigen loci (HLA) (HLA-A, HLA-B, HLA-DR) should be sufficient for matching the recipient to minimize and overcome the risk of immunogenicity [52, 53].”
BackgroundInduced pluripotent stem cells: history, properties and potential applications.
Nordin, N., Lai, M. I., Veerakumarasivam, A., Ramasamy, R., Abdullah, S., Wendy-Yeo, W. Y., & Rosli, R. (2011) · PubMed · Cited by 18
Elimination of blood group antigens: hope and reality
Bagnis, C., Chiaroni, J., & Bailly, P. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08561.x · Cited by 15
“A Japanese group has proposed creating an exhaustive bank of Japanese ES cell lines for use in cell transplantation therapy (Nakajima et al, 2007; Nakatsuji et al, 2008).”
BackgroundAnalysis of Haplotype Sequences
Lloyd, S. S., Steele, E. J., & Dawkins, R. L. (2016) · InTech eBooks · doi:10.5772/61794 · Cited by 15
Robust Cardiac Regeneration: Fulfilling the Promise of Cardiac Cell Therapy
Selvakumar, D., Clayton, Z. E., & Chong, J. J. H. (2020) · Clinical Therapeutics · doi:10.1016/j.clinthera.2020.08.008 · Cited by 15
Immunological Considerations for Retinal Stem Cell Therapy
Kramer, J., Chirco, K. R., & Lamba, D. A. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-28471-8_4 · Cited by 14
Pluripotent Stem Cells in Research and Treatment of Hemoglobinopathies
Arora, N., & Daley, G. Q. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a011841 · Cited by 15
“In the Japanese population, a cell bank of 170 human PSC lines would provide a single mismatch or better for 80% of patients (Nakajima et al. 2007), whereas a cell bank of 30 highly selected homozygous human PSC lines would provide a full match for 82.”
BackgroundInfluentialSung, T., Jiang, Y., Hsu, J., Ling, Q., Chen, H., Kumar, S. S., Chang, Y., Hsu, S., Ye, Q., & Higuchi, A. (2021) · Cell Proliferation · doi:10.1111/cpr.12995 · Cited by 12
Swelstad, B. B., & Kerr, C. L. (2009) · Stem Cells and Cloning Advances and Applications · doi:10.2147/sccaa.s8051 · Cited by 15
Augmentation of Musculoskeletal Regeneration: Role for Pluripotent Stem Cells
Jevons, L. A., Houghton, F. D., & Tare, R. S. (2018) · Regenerative Medicine · doi:10.2217/rme-2017-0113 · Cited by 14
Yang, H.-M., Moon, S., Choi, Y., Park, S., Lee, Y., Lee, H.-J., Kim, S.-J., & Chung, H. (2013) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.113.302462 · Cited by 13
“Based on the HLA type, it has been estimated that ≈170 hESC lines would be required to provide 1 hESC line carrying only a single HLA mismatch to 80% of the patients in Japan.(35) Therefore, the generation of patient-specific stem cell lines has been proposed in the form of induced pluripotent stem cells to avoid comp…”
BackgroundHuman pluripotent stem cells in regenerative medicine: where do we stand?
Nguyen, H. T., Jacobs, K., & Spits, C. (2018) · Reproduction · doi:10.1530/rep-18-0291 · Cited by 13
“For a hESC bank, on the other hand, lines derived from 170 randomly selected donated embryos would provide at least one hESC line with a single mismatch at one locus or better match for 80% of patients (Nakajima et al. 2007).”
MethodMorishima, Y., Azuma, F., Kashiwase, K., Matsumoto, K., Orihara, T., Yabe, H., Kato, S., Kato, K., Kai, S., Mori, T., et al. (2017) · Stem Cells Translational Medicine · doi:10.1002/sctm.17-0169 · Cited by 11
Okita, K. (2010) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0b013e32834252a2 · Cited by 14
Fisher, M. C. (2012) · Rheumatology Current Research · doi:10.4172/2161-1149.s3-004 · Cited by 11
“Studies estimate that such a bank would require between 150-170 hESC lines to provide HLA (Human Leukocyte Antigen) matching for populations in the United Kingdom and Japan with minimal immune suppression required [110,111], and an established 188-line hESC bank created in China is planned to provide HLA matching for…”
Background
Metadata
- Authors
- Nakajima, F., Tokunaga, K., & Nakatsuji, N.
- Affiliations
- Japanese Red Cross Society, Japan (JP)
- The University of Tokyo (JP)
- Kyoto University (JP)
- Corresponding author
- Tokunaga, Katsushi
- Nakatsuji, Norio
- Venue
- Stem Cells
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-12-21
- Volume
- 25
- Issue
- 4
- Pages
- 983-985
- ISSN
- 1066-5099 (ISSN-L)
- 1549-4918
- OpenAlex
- W2093267077
- Cited by
- 168
- References
- 15
- Citations by year
- 2025: 1 · 2024: 3 · 2023: 4 · 2022: 11 · 2021: 4 · 2020: 6 · 2019: 7 · 2018: 9 · 2017: 9 · 2016: 13 · 2015: 14 · 2014: 12 · 2013: 10 · 2012: 19
- FWCI
- 2.18
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Stem Cells (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Ministry of Education, Science and Technology
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Health Sciences › Nursing › Issues, ethics and legal aspects › Biomedical Ethics and Regulation
- Keywords
- human embryonic stem cell lines, HLA matching, HLA typing, stem cell banking, allogeneic cell transplantation, immunosuppression, HLA-A, HLA-B, HLA-DR, parthenogenetic embryos, Japanese population, ethnic diversity, donor availability
- MeSH terms
- Cell Line, Family, Female, Histocompatibility Testing, HLA Antigens, Humans, Japan, Male, Parthenogenesis, Tissue Banks, Stem Cell Transplantation, Cord Blood Stem Cell Transplantation, Embryonic Stem Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.